Deutsch English Français

Contact

EP1053009

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1053009

EP1053009 - USE OF HEREGULIN AS AN EPITHELIAL CELL GROWTH FACTOR [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 29.07.2005 Database last updated on 23.04.2024
Most recent event Tooltip	21.03.2008	Lapse of the patent in a contracting state New state(s): IT, PT	published on 23.04.2008 [2008/17]
Applicant(s)	For all designated states Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 / US
	For all designated states UNIVERSITY OF IOWA RESEARCH FOUNDATION 100 Oakdale Campus 214 TIC Iowa City, IA 55242-5000 / US
	[N/P]
Former [2000/47]	For all designated states Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 / US
	For all designated states University of Iowa Research Foundation 100 Oakdale Campus 214 TIC Iowa City, IA 55242-5000 / US
Inventor(s)	01 / SLIWKOWSKI, Mark 42 Oak Creek Lane Iowa City, IA 94070 / US
	02 / KERN, Jeffrey, A. 4344 Maier Avenue Iowa City, IA 52240 / US
	[2000/47]
Representative(s)	Kiddle, Simon John, et al Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB
	[N/P]
Former [2000/47]	Kiddle, Simon John, et al Mewburn Ellis, York House, 23 Kingsway London WC2B 6HP / GB
Application number, filing date	99905717.7	03.02.1999
	[2000/47]
	WO1999US02390
Priority number, date	US19980020598	04.02.1998 Original published format: US 20598
	[2000/47]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO9939729
	Date:	12.08.1999
	Language:	EN
	[1999/32]
	Type:	A2 Application without search report
	No.:	EP1053009
	Date:	22.11.2000
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 12.08.1999 takes the place of the publication of the European patent application.
	[2000/47]
	Type:	B1 Patent specification
	No.:	EP1053009
	Date:	22.09.2004
	Language:	EN
	[2004/39]
Search report(s)	International search report - published on:	EP	14.10.1999
Classification	IPC:	A61K38/18, A61K39/395, A61K38/17, A61K35/12, // (C07K14/475, 16:22, C12N15:12, C12P21:08)	[2000/47]
	CPC:	C07K16/22 (EP,US); A61P11/00 (EP); A61P43/00 (EP); C07K14/4756 (EP,US); A61K38/00 (EP,US); C07K2319/30 (EP,US); (+) C12N2810/40 (EP,US) (-)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2000/47]
Title	German:	VERWENDUNG DES HEREGULINS ALS EPITHELZELLENWACHSTUMSFAKTOR	[2000/47]
	English:	USE OF HEREGULIN AS AN EPITHELIAL CELL GROWTH FACTOR	[2000/47]
	French:	UTILISATION DE L'HEREGULINE COMME FACTEUR DE CROISSANCE DE CELLULE EPITHELIALE	[2000/47]
Entry into regional phase	24.08.2000	National basic fee paid
	24.08.2000	Designation fee(s) paid
	24.08.2000	Examination fee paid
Examination procedure	25.08.1999	Request for preliminary examination filed International Preliminary Examining Authority: EP
	24.08.2000	Examination requested [2000/47]
	22.01.2001	Despatch of a communication from the examining division (Time limit: M06)
	06.09.2001	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	14.12.2001	Reply to a communication from the examining division
	18.03.2002	Despatch of a communication from the examining division (Time limit: M06)
	30.09.2002	Reply to a communication from the examining division
	20.11.2002	Despatch of a communication from the examining division (Time limit: M08)
	28.07.2003	Reply to a communication from the examining division
	09.01.2004	Communication of intention to grant the patent
	14.07.2004	Fee for grant paid
	14.07.2004	Fee for publishing/printing paid
Divisional application(s)	EP04022325.7 / EP1510579
Opposition(s)	23.06.2005	No opposition filed within time limit [2005/37]
Request for further processing for:	14.12.2001	Request for further processing filed
	14.12.2001	Full payment received (date of receipt of payment) Request granted
	14.01.2002	Decision despatched
Fees paid	Renewal fee
	15.02.2001	Renewal fee patent year 03
	13.02.2002	Renewal fee patent year 04
	12.02.2003	Renewal fee patent year 05
	12.02.2004	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AT	22.09.2004
	FI	22.09.2004
	IT	22.09.2004
	NL	22.09.2004
	DK	22.12.2004
	GR	22.12.2004
	SE	22.12.2004
	CY	03.02.2005
	PT	22.02.2005
	[2008/17]
Former [2007/22]	AT	22.09.2004
	FI	22.09.2004
	NL	22.09.2004
	DK	22.12.2004
	GR	22.12.2004
	SE	22.12.2004
	CY	03.02.2005
Former [2006/14]	AT	22.09.2004
	FI	22.09.2004
	NL	22.09.2004
	DK	22.12.2004
	GR	22.12.2004
	SE	22.12.2004
Former [2005/46]	AT	22.09.2004
	FI	22.09.2004
	DK	22.12.2004
	GR	22.12.2004
	SE	22.12.2004
Former [2005/18]	AT	22.09.2004
	FI	22.09.2004
	GR	22.12.2004
	SE	22.12.2004
Former [2005/13]	AT	22.09.2004
	FI	22.09.2004
	SE	22.12.2004
Former [2005/11]	FI	22.09.2004
	SE	22.12.2004
Former [2005/10]	SE	22.12.2004
Cited in	International search	[X]US5367060 (VANDLEN RICHARD L [US], et al) [X] 1-6,8-20 * column W *;
		[A]WO9615244 (GENENTECH INC [US], et al) [A] 1,8,10* the whole document *;
		[X] - PATEL, N. V. ET AL, "Heregulin (HRG) and human epidermal receptor ( HER ) 2 and 3 are modulated during in vitro human lung growth and differentiation.", JOURNAL OF INVESTIGATIVE MEDICINE, (1997) VOL. 45, NO. 3, PP. 284A, XP002113357 [X] 1-6,8-20 * the whole document *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p